Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1825 1
1844 1
1848 1
1849 1
1855 3
1866 2
1869 2
1873 5
1876 1
1892 1
1893 2
1895 2
1897 1
1898 3
1899 1
1900 2
1903 2
1904 1
1905 4
1907 1
1908 1
1909 2
1910 1
1911 2
1912 2
1913 3
1914 1
1915 1
1916 1
1917 2
1918 5
1919 4
1920 3
1921 2
1922 3
1924 3
1925 5
1926 4
1927 2
1928 2
1930 4
1931 2
1932 2
1934 1
1936 1
1938 1
1939 1
1941 1
1942 1
1944 1
1945 8
1946 34
1947 13
1948 113
1949 76
1950 106
1951 99
1952 114
1953 103
1954 136
1955 118
1956 112
1957 119
1958 124
1959 82
1960 4
1961 7
1962 6
1963 112
1964 184
1965 153
1966 103
1967 156
1968 132
1969 152
1970 130
1971 128
1972 167
1973 150
1974 149
1975 360
1976 429
1977 385
1978 448
1979 585
1980 629
1981 740
1982 853
1983 1050
1984 1148
1985 1145
1986 1182
1987 1280
1988 1314
1989 1623
1990 1626
1991 1690
1992 1798
1993 2062
1994 2154
1995 2229
1996 2394
1997 2525
1998 2685
1999 2796
2000 3239
2001 3273
2002 3605
2003 3944
2004 4354
2005 4839
2006 5335
2007 5913
2008 6600
2009 7039
2010 7922
2011 9287
2012 10264
2013 11975
2014 13074
2015 14060
2016 15049
2017 16342
2018 17392
2019 18868
2020 22072
2021 25599
2022 26098
2023 25261
2024 26402
2025 32267
2026 8436

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

340,230 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for met for
Search for Meet Gor instead (1 results)
MET Oncogene Targeting for Cancer Immunotherapy.
Lombardi AM, Sangiolo D, Vigna E. Lombardi AM, et al. Int J Mol Sci. 2024 Jun 1;25(11):6109. doi: 10.3390/ijms25116109. Int J Mol Sci. 2024. PMID: 38892318 Free PMC article. Review.
MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expressio …
MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era …
An Observatory for the MET Oncogene: A Guide for Targeted Therapies.
Altintas DM, Comoglio PM. Altintas DM, et al. Cancers (Basel). 2023 Sep 21;15(18):4672. doi: 10.3390/cancers15184672. Cancers (Basel). 2023. PMID: 37760640 Free PMC article. Review.
The pleiotropic physiological functions of MET explain its diverse role in cancer progression in a broad range of tumors; genetic/epigenetic alterations of MET drive tumor cell dissemination, metastasis, and acquired resistance to conventional and targeted therapies …
The pleiotropic physiological functions of MET explain its diverse role in cancer progression in a broad range of tumors; genetic/epi …
MET Inhibitors for the Treatment of Gastric Cancer: What's Their Potential?
El Darsa H, El Sayed R, Abdel-Rahman O. El Darsa H, et al. J Exp Pharmacol. 2020 Oct 6;12:349-361. doi: 10.2147/JEP.S242958. eCollection 2020. J Exp Pharmacol. 2020. PMID: 33116950 Free PMC article. Review.
Tyrosine kinase inhibitors targeting the HGF/MET pathway were studied in MET-positive gastric cancer, but no substantial benefit was proven. ...Etiologies of resistance may entail inappropriate patient selection with a lack of MET detection standardization, t …
Tyrosine kinase inhibitors targeting the HGF/MET pathway were studied in MET-positive gastric cancer, but no substantial benef …
Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC.
Jørgensen JT, Mollerup J. Jørgensen JT, et al. Cancers (Basel). 2022 Apr 26;14(9):2150. doi: 10.3390/cancers14092150. Cancers (Basel). 2022. PMID: 35565287 Free PMC article. Review.
An alternative predictive biomarker for MET therapy is MET amplification, which has been identified as a resistance mechanism in patients with EGFR-mutated NSCLC. Results obtained from different clinical trials seem to indicate that the MET/CEP7 ratio detecte …
An alternative predictive biomarker for MET therapy is MET amplification, which has been identified as a resistance mechanism …
Overview of Molecular Detection Technologies for MET in Lung Cancer.
Heydt C, Ihle MA, Merkelbach-Bruse S. Heydt C, et al. Cancers (Basel). 2023 May 26;15(11):2932. doi: 10.3390/cancers15112932. Cancers (Basel). 2023. PMID: 37296895 Free PMC article. Review.
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET proto-oncogene, including MET overexpression, the activation of MET mutations, MET mutations that lead to MET …
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the MET …
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
Garon EB, Brodrick P. Garon EB, et al. Drugs. 2021 Apr;81(5):547-554. doi: 10.1007/s40265-021-01477-2. Epub 2021 Feb 27. Drugs. 2021. PMID: 33638808 Review.
Unlike MET overexpression, MET amplification has demonstrated a stronger potential as a biomarker for therapeutic treatment, with clinical data indicating a compelling connection between a high MET gene copy number and a high response rate to targeted therapi …
Unlike MET overexpression, MET amplification has demonstrated a stronger potential as a biomarker for therapeutic treatment, w …
MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. Guo R, et al. Nat Rev Clin Oncol. 2020 Sep;17(9):569-587. doi: 10.1038/s41571-020-0377-z. Epub 2020 Jun 8. Nat Rev Clin Oncol. 2020. PMID: 32514147 Free PMC article. Review.
Attempts to develop MET-targeted therapies have historically focused on MET-expressing cancers, with limited success. Thus, MET expression in the absence of a genomic marker of MET dependence is a poor predictor of benefit from MET-targeted ther …
Attempts to develop MET-targeted therapies have historically focused on MET-expressing cancers, with limited success. Thus, …
c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD, Shanmugam MK, Gowda SGS, Chinnathambi A, Rangappa KS, Sethi G. Mohan CD, et al. Phytomedicine. 2024 Jun;128:155379. doi: 10.1016/j.phymed.2024.155379. Epub 2024 Jan 18. Phytomedicine. 2024. PMID: 38503157 Review.
The c-MET pathway is deregulated in a broad range of malignancies, due to overexpression of ligands or receptors, genomic amplification, and MET mutations. ...Some of the keywords used for extracting relevant literature are c-MET, natural compound inhibitors …
The c-MET pathway is deregulated in a broad range of malignancies, due to overexpression of ligands or receptors, genomic amplificati …
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Kawakami H, Okamoto I. Kawakami H, et al. Gastric Cancer. 2016 Jul;19(3):687-95. doi: 10.1007/s10120-015-0585-x. Epub 2015 Dec 21. Gastric Cancer. 2016. PMID: 26690587 Review.
On the other hand, gastric cancer cells with MET amplification are dependent on MET signaling for their survival and are thus vulnerable to MET TKI treatment. ...We compare aberrant MET signaling dependent on the HGF-MET axis or on MET am …
On the other hand, gastric cancer cells with MET amplification are dependent on MET signaling for their survival and are thus …
ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.
Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB. Wang J, et al. Clin Cancer Res. 2017 Feb 15;23(4):992-1000. doi: 10.1158/1078-0432.CCR-16-1568. Epub 2016 Aug 29. Clin Cancer Res. 2017. PMID: 27573171
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted only small subsets of patients with tumors driven by signaling through the c-Met pathway, thereby necessitating selection of patients …
Purpose: Despite the importance of the MET oncogene in many malignancies, clinical strategies targeting c-Met have benefitted …
340,230 results
You have reached the last available page of results. Please see the User Guide for more information.